Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor - 03/07/19
Résumé |
The introduction of cisplatin-based chemotherapy has revolutionized the care of patients with disseminated testicular germ cell tumors. Although a majority are cured with chemotherapy alone, surgical resection continues to play a role because one-third will have residual mass after chemotherapy. In this article, we review the current indications for postchemotherapy resection in nonseminomatous germ cell tumors, including masses greater than 1 cm, resection after salvage chemotherapy, with elevated markers, after late relapse, and for growing teratoma syndrome. We also highlight technical considerations of this often-challenging surgery, including the need for adjunctive procedures, extraretroperitoneal resections, and modern techniques to minimize morbidity.
Le texte complet de cet article est disponible en PDF.Keywords : Germ cell tumor, Testicular cancer, Nonseminomatous, Retroperitoneal lymph node dissection
Plan
Disclosure Statement: The authors have nothing to disclose. |
Vol 46 - N° 3
P. 389-398 - août 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?